论文期刊

取消

高级检索

检索历史清除

首页> Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie> ELK1-induced upregulation of long non-coding RNA MIR100HG predicts poor prognosis and promotes the progression of osteosarcoma by epigenetically silencing LATS1 and LATS2.

ELK1-induced upregulation of long non-coding RNA MIR100HG predicts poor prognosis and promotes the progression of osteosarcoma by epigenetically silencing LATS1 and LATS2.

导出 LinkOut

翻译打印收藏纠错

作者： Xiaochuan,Su ^[1] ; Junyan,Teng ^[1] ; Guoguo,Jin ^[2] ; Jitian,Li ^[2] ; Zhenjiang,Zhao ^[1] ; Xiangyang,Cao ^[1] ; Yanxing,Guo ^[1] ; Malong,Guo ^[1] ; Xiaoling,Li ^[1] ; Jun,Wu ^[1] ; Chuanzhen,Wang ^[1] ; Zhiping,Guo ^[3] ; Qing,Guo ^[4]

作者单位： Department of Osteoarthrosis & Health Management Center, Henan Luoyang Orthopedic Hospital, Henan Provincial Orthopedic Hospital, No.100, Yongping Road, Zhengzhou, Henan Province, 450046, China. ^[1] Laboratory of Bone Tumor, Henan Luoyang Orthopedic Hospital, No.100, Yongping Road, Zhengzhou, Henan Province, 450046, China. ^[2] Laboratory of Bone Tumor, Henan Luoyang Orthopedic Hospital, No.100, Yongping Road, Zhengzhou, Henan Province, 450046, China. Electronic address: ZhipingGuoDr_GZP@163.com. ^[3] Zhejiang Chinese Medical University, No.548 Bingwen road, Bingjiang district, Hangzhou, Zhejiang province, 310053, China. Electronic address: Qing_Guo334@163.com. ^[4]

关键词 ELK1 Hippo signaling pathway MIR100HG Osteosarcoma Proliferation

主题词成年人(Adult);骨肿瘤(Bone Neoplasms);细胞系, 肿瘤(Cell Line, Tumor);疾病恶化(Disease Progression);后成说, 遗传(Epigenesis, Genetic);女(雌)性(Female);人类(Humans);男(雄)性(Male);微RNAs(MicroRNAs);中年人(Middle Aged);骨肉瘤(Osteosarcoma);肿瘤抑制蛋白质类(Tumor Suppressor Proteins);增量调节(Up-Regulation);ets结构域蛋白Elk1(ets-Domain Protein Elk-1)

DOI 10.1016/j.biopha.2018.10.029

PMID 30551532

发布时间 2022-04-08

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览12

Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie

788-797页

相似文献

中文期刊
外文期刊
学位论文
会议论文

特别提示：本网站仅提供医学学术资源服务，不销售任何药品和器械，有关药品和器械的销售信息，请查阅其他网站。

客服热线：4000-115-888 转3 (周一至周五：8:00至17:00)
|
客服邮箱：yiyao@wanfangdata.com.cn

违法和不良信息举报电话：4000-115-888，举报邮箱：problem@wanfangdata.com.cn，举报专区

官方微信

万方医学小程序

关于我们网站地图知识产权

北京万方数据股份有限公司

万方数据电子出版社

京ICP证010071号

京公网安备11010802020237号

京ICP备08100800号-1

违法和不良信息举报电话：4000-115-888，举报邮箱：problem@wanfangdata.com.cn，举报专区

new翻译充值订阅收藏移动端

官方微信

万方医学小程序

调查问卷